VAUGHAN & Co SECURITIES INC. Acquires New Shares in Bristol-Myers Squibb (NYSE:BMY)

VAUGHAN & Co SECURITIES INC. bought a new position in Bristol-Myers Squibb (NYSE:BMY) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 16,622 shares of the biopharmaceutical company’s stock, valued at approximately $690,000. Bristol-Myers Squibb comprises approximately 0.4% of VAUGHAN & Co SECURITIES INC.’s portfolio, making the stock its 26th biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. Great Diamond Partners LLC increased its stake in Bristol-Myers Squibb by 9.2% in the 4th quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 367 shares during the last quarter. Global Assets Advisory LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth about $5,161,000. Principal Securities Inc. purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $1,139,000. Lincoln National Corp boosted its holdings in shares of Bristol-Myers Squibb by 7.7% in the 1st quarter. Lincoln National Corp now owns 42,894 shares of the biopharmaceutical company’s stock worth $2,326,000 after purchasing an additional 3,052 shares in the last quarter. Finally, Chapin Davis Inc. boosted its holdings in shares of Bristol-Myers Squibb by 22.6% in the 1st quarter. Chapin Davis Inc. now owns 22,544 shares of the biopharmaceutical company’s stock worth $1,223,000 after purchasing an additional 4,159 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BMY. Jefferies Financial Group upped their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen increased their target price on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday, August 12th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Barclays increased their target price on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $54.67.

Bristol-Myers Squibb Stock Up 0.5 %

Shares of NYSE:BMY traded up $0.23 during trading on Friday, hitting $49.95. The stock had a trading volume of 9,594,794 shares, compared to its average volume of 15,441,344. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.03. The company has a market capitalization of $101.25 billion, a PE ratio of -16.11, a PEG ratio of 12.51 and a beta of 0.44. The firm’s fifty day moving average is $45.17 and its 200 day moving average is $46.59. The company has a quick ratio of 0.99, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The company had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $1.75 EPS. Analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.80%. The ex-dividend date of this dividend was Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.